Search Results - "Gleave, M.E"

The Future of Systemic Therapies for Localised Prostate Cancer by Eigl, B.J, Gleave, M.E, Chi, K.N

“…Abstract In the last decade, many systemic therapies have become available to improve survival in the setting of castration-resistant prostate cancer. Once…”
Get full text

P03-26 Insulin-like Growth Factor-II increases de novo steroidogenesis in prostate cancer cells by Lubik, A.A, Gunter, J.H, Ettinger, S, Fazil, L, Stylianou, N, Hendy, S.C, Adomat, H.H, Hollier, B.G, Gleave, M.E, Pollak, M, Herington, A.C, Nelson, C.C

Get full text

GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer by Li, N, Zoubeidi, A, Beraldi, E, Gleave, M E

“…Expression of clusterin (CLU) closely correlates with the regulation of apoptosis in cancer. Although endoplasmic reticulum (ER) stress-induced upregulation…”
Get full text

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 by Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P.S., Sartor, O., Smith, M.R., Soule, H.R., Akaza, H., Beer, T.M., Beltran, H., Chinnaiyan, A.M., Daugaard, G., Davis, I.D., De Santis, M., Drake, C.G., Eeles, R.A., Fanti, S., Gleave, M.E., Heidenreich, A., Hussain, M., James, N.D., Lecouvet, F.E., Logothetis, C.J., Mastris, K., Nilsson, S., Oh, W.K., Olmos, D., Padhani, A.R., Parker, C., Rubin, M.A., Schalken, J.A., Scher, H.I., Sella, A., Shore, N.D., Small, E.J., Sternberg, C.N., Suzuki, H., Sweeney, C.J., Tannock, I.F., Tombal, B.

“…The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most…”
Get full text

1766MO Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical recurrence (BCR) from the EMBARK study by Freedland, S.J., Gleave, M.E., De Giorgi, U.F.F., Rannikko, A., Pieczonka, C., Tutrone, R., Venugopal, B., Woo, H., Ramirez Backhaus, M., Supiot, S., Lantz, A., Ganguli, A., Ivanova, J., Kral, P., Huang, S-P., Saad, F., Shore, N.D.

Get full text

1777P Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints by De Giorgi, U.F.F., Freedland, S.J., Gleave, M.E., Tutrone, R., Bailen, J.L., Roos, E., Kliment, J., Marx, G.M., Karsh, L.I., Ramirez-Backhaus, M., Uchio, E., Supiot, S., Tang, Y., Rosbrook, B., Haas, G.P., Rosales, M., Zohren, F., Shore, N.D.

Get full text

1778P Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK by Freedland, S.J., Gleave, M.E., De Giorgi, U.F.F., Rannikko, A., Pieczonka, C., Sridharan, S., Brasso, K., Woo, H., Gomez Caamaño, A., Saranchuk, J., Nordquist, L.T., Ferreira, U., Tang, Y., Rosbrook, B., Haas, G.P., Rosales, M., Zohren, F., Shore, N.D.

Get full text

A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers by Chi, K.N., Yu, E.Y., Jacobs, C., Bazov, J., Kollmannsberger, C., Higano, C.S., Mukherjee, S.D., Gleave, M.E., Stewart, P.S., Hotte, S.J.

“…Heat shock protein 27 (Hsp27) is a chaperone protein that regulates cell survival via androgen receptor and other signaling pathways, thereby mediating cancer…”
Get full text

Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy by Nappi, L., Thi, M., Eigl, B.J., Chi, K.N., Gleave, M.E., So, A., Black, P.C., Hamilton, R., Daneshmand, S., Nichols, C.R., Kollmannsberger, C.K.

Get full text

983P - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy by Nappi, L., Thi, M., Eigl, B.J., Chi, K.N., Gleave, M.E., So, A., Black, P.C., Hamilton, R., Daneshmand, S., Nichols, C.R., Kollmannsberger, C.K.

“…MicroRNAs are examined for clinical utility in active germ cell malignancies (GCM). miR-371a-3p (miR371) has a very high specificity and high sensitivity for…”
Get full text

220 The risks and benefits of extended pelvic lymph node dissection in patients undergoing radical cystectomy by Abdi, H, Pourmalek, F, Gleave, M.E, So, A.I, Black, P.C

Get full text

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies by Khalaf, D.J., Aragón, I.M., Annala, M., Lozano, R., Taavitsainen, S., Lorente, D., Finch, D.L., Romero-Laorden, N., Vergidis, J., Cendón, Y., Oja, C., Pacheco, M.I., Zulfiqar, M., Almagro, E., Arranz, J.Á., Billalabeitia, E.G., Borrega, P., Castro, E., Contreras, J.A., Domenech, M., Escribano, R., Fernández-Parra, E., Gallardo, E., García-Carbonero, I., García, R., Garde, J., González del Alba, A., González, B., Hernández, A., Hernando, S., Jiménez, P., Laínez, N., Lorente, D., Luque, R., Martínez, E., Medina, A., Méndez-Vidal, M.J., Montesa, A., Morales, R., Olmos David, Pérez-Gracia, J.L., Pérez-Valderrama, B., Pinto, Á., Piulats, J., Puente, J., Querol, R., Rodríguez-Vida, A., Romero-Laorden, N., Sáez, M.I., Vázquez, S., Vélez, E., Villa-Guzmán, J.C., Villatoro, R., Zambrana, C., Gleave, M.E., Wyatt, A.W., Olmos, D., Chi, K.N., Castro, E.

“…A common polymorphism (1245A>C) in the HSD3B1 gene is associated with increased de novo synthesis of androgens and worse outcomes in men treated with…”
Get full text

245 Downregulation of Hsp27 using OGX-427 induces ER stress and potentiates Hsp90 inhibitors to delay castrate resistant prostate cancer by Lamoureux, F, Yin, M.J, Zoubeidi, A, Gleave, M.E

Get full text

Detection of circulating tumor DNA in de novo metastatic castrate sensitive prostate cancer by Struss, W.J., Vandekerkhove, G., Annala, M., Chi, K.N., Gleave, M.E., Wyatt, A.

Get full text

516 Targeting IGF-BP2 and 5 with the bispecific antisense oligodeoxynucleotide OGX-225 in chemoresistant bladder cancer by Jäger, W, Hayashi, T, Ischia, J, Janßen, C, Awrey, S, Fazli, L, Gleave, M.E, Black, P.C

Get full text

30 Active surveillance in 853 men with low and intermediate risk prostate cancer by Aning, J.J, Peacock, M, Zargar, H, McKenzie, M, Black, P.B, So, A.I, Goldenberg, S.L, Gleave, M.E

Get full text

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 by Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P.S., Sartor, O., Smith, M.R., Soule, H.R., Akaza, H., Beer, T.M., Beltran, H., Chinnaiyan, A.M., Daugaard, G., Davis, I.D., De Santis, M., Drake, C.G., Eeles, R.A., Fanti, S., Gleave, M.E., Heidenreich, A., Hussain, M., James, N.D., Lecouvet, F.E., Logothetis, C.J., Mastris, K., Nilsson, S., Oh, W.K., Olmos, D., Padhani, A.R., Parker, C., Rubin, M.A., Schalken, J.A., Scher, H.I., Sella, A., Shore, N.D., Small, E.J., Sternberg, C.N., Suzuki, H., Sweeney, C.J., Tannock, I.F., Tombal, B.

Get full text

Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies by Tretiakova, M S, Wei, W, Boyer, H D, Newcomb, L F, Hawley, S, Auman, H, Vakar-Lopez, F, McKenney, J K, Fazli, L, Simko, J, Troyer, D A, Hurtado-Coll, A, Thompson, I M, Carroll, P R, Ellis, W J, Gleave, M E, Nelson, P S, Lin, D W, True, L D, Feng, Z, Brooks, J D

“…Background: Expanding interest in and use of active surveillance for early state prostate cancer (PC) has increased need for prognostic biomarkers. Using a…”
Get full text

Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy by Wyatt, A.W., Annala, M., Beja, K., Parimi, S., Vandekerkhove, G., Warner, E., Zulfiqar, M., Finch, D., Oja, C., Vergidis, J., Nykter, M., Gleave, M.E., Chi, K.

Get full text

959 The role of multi-parametric MRI in the management of patients on active surveillance for prostate cancer by Abdi, H, Walshe, T, Pourmalek, F, Aning, J.J, Zargar, H, Harris, A.C, Chang, S.D, So, A.I, Gleave, M.E, Machan, L, Black, P.C, Goldenberg, S.L

Get full text